Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidl...
Joining ReMY on the round were new investors Boro Capital, Supernode Ventures, MedMountain Ventures, The Triangle Tweener Fund, David Golan, and Silic...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that its CE...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease an...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
Agilent Technologies Inc. (NYSE: A) announced the results of an independent third-party global survey that will help the industry better unders...
“The acquisition of VGYAAN Pharmaceuticals aligns strongly with our growth strategy that will deliver substantial value for our company, customers, a...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
© 2025 Biopharma Boardroom. All Rights Reserved.
